Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

Alfonso Quintás-Cardama, Hagop Kantarjian, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, Srdan Verstovsek, Jianqin Shan, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

We investigated the impact of carrying more than one BCRABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8%) of 92 patients carrying mutations had more than one mutation: 4 (4%) in chronic phase, 2 (2%) in accelerated phase, and one (1%) in blast phase. The cytogenetic response rate to second generation TKIs for patients with no, one, or more than one mutation was 88%, 69%, 50% (P=0.03) in chronic phase, 54%, 42%, 50% in accelerated phase (P=0.67), and 35%, 25%, 0% (P=0.63) in blast phase, respectively. No differences were observed in event free survival or overall survival in accelerated or blast phase according to their mutational status. However, the 4-year event free survival rates among patients in chronic phase with no, one, or more than one BCR-ABL1 mutation were 56%, 49%, and 0%, respectively (P=0.02), with overall survival rates of 91%, 69%, and 75%, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation.

Original languageEnglish (US)
Pages (from-to)918-921
Number of pages4
JournalHaematologica
Volume96
Issue number6
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Phosphotransferases
Blast Crisis
Mutation
Therapeutics
Disease-Free Survival
Survival Rate
Cytogenetics
Survival

Keywords

  • ABL1 mutation
  • CML
  • Multiple mutations
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. / Quintás-Cardama, Alfonso; Kantarjian, Hagop; O'Brien, Susan; Jabbour, Elias; Borthakur, Gautam; Ravandi, Farhad; Verstovsek, Srdan; Shan, Jianqin; Cortes, Jorge.

In: Haematologica, Vol. 96, No. 6, 01.06.2011, p. 918-921.

Research output: Contribution to journalArticle

Quintás-Cardama, A, Kantarjian, H, O'Brien, S, Jabbour, E, Borthakur, G, Ravandi, F, Verstovsek, S, Shan, J & Cortes, J 2011, 'Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy', Haematologica, vol. 96, no. 6, pp. 918-921. https://doi.org/10.3324/haematol.2010.039321
Quintás-Cardama, Alfonso ; Kantarjian, Hagop ; O'Brien, Susan ; Jabbour, Elias ; Borthakur, Gautam ; Ravandi, Farhad ; Verstovsek, Srdan ; Shan, Jianqin ; Cortes, Jorge. / Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. In: Haematologica. 2011 ; Vol. 96, No. 6. pp. 918-921.
@article{d748ec688b0d45ceb63c39fe0a056bd9,
title = "Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy",
abstract = "We investigated the impact of carrying more than one BCRABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8{\%}) of 92 patients carrying mutations had more than one mutation: 4 (4{\%}) in chronic phase, 2 (2{\%}) in accelerated phase, and one (1{\%}) in blast phase. The cytogenetic response rate to second generation TKIs for patients with no, one, or more than one mutation was 88{\%}, 69{\%}, 50{\%} (P=0.03) in chronic phase, 54{\%}, 42{\%}, 50{\%} in accelerated phase (P=0.67), and 35{\%}, 25{\%}, 0{\%} (P=0.63) in blast phase, respectively. No differences were observed in event free survival or overall survival in accelerated or blast phase according to their mutational status. However, the 4-year event free survival rates among patients in chronic phase with no, one, or more than one BCR-ABL1 mutation were 56{\%}, 49{\%}, and 0{\%}, respectively (P=0.02), with overall survival rates of 91{\%}, 69{\%}, and 75{\%}, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation.",
keywords = "ABL1 mutation, CML, Multiple mutations, Tyrosine kinase inhibitor",
author = "Alfonso Quint{\'a}s-Cardama and Hagop Kantarjian and Susan O'Brien and Elias Jabbour and Gautam Borthakur and Farhad Ravandi and Srdan Verstovsek and Jianqin Shan and Jorge Cortes",
year = "2011",
month = "6",
day = "1",
doi = "10.3324/haematol.2010.039321",
language = "English (US)",
volume = "96",
pages = "918--921",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "6",

}

TY - JOUR

T1 - Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

AU - Quintás-Cardama, Alfonso

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Jabbour, Elias

AU - Borthakur, Gautam

AU - Ravandi, Farhad

AU - Verstovsek, Srdan

AU - Shan, Jianqin

AU - Cortes, Jorge

PY - 2011/6/1

Y1 - 2011/6/1

N2 - We investigated the impact of carrying more than one BCRABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8%) of 92 patients carrying mutations had more than one mutation: 4 (4%) in chronic phase, 2 (2%) in accelerated phase, and one (1%) in blast phase. The cytogenetic response rate to second generation TKIs for patients with no, one, or more than one mutation was 88%, 69%, 50% (P=0.03) in chronic phase, 54%, 42%, 50% in accelerated phase (P=0.67), and 35%, 25%, 0% (P=0.63) in blast phase, respectively. No differences were observed in event free survival or overall survival in accelerated or blast phase according to their mutational status. However, the 4-year event free survival rates among patients in chronic phase with no, one, or more than one BCR-ABL1 mutation were 56%, 49%, and 0%, respectively (P=0.02), with overall survival rates of 91%, 69%, and 75%, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation.

AB - We investigated the impact of carrying more than one BCRABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8%) of 92 patients carrying mutations had more than one mutation: 4 (4%) in chronic phase, 2 (2%) in accelerated phase, and one (1%) in blast phase. The cytogenetic response rate to second generation TKIs for patients with no, one, or more than one mutation was 88%, 69%, 50% (P=0.03) in chronic phase, 54%, 42%, 50% in accelerated phase (P=0.67), and 35%, 25%, 0% (P=0.63) in blast phase, respectively. No differences were observed in event free survival or overall survival in accelerated or blast phase according to their mutational status. However, the 4-year event free survival rates among patients in chronic phase with no, one, or more than one BCR-ABL1 mutation were 56%, 49%, and 0%, respectively (P=0.02), with overall survival rates of 91%, 69%, and 75%, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation.

KW - ABL1 mutation

KW - CML

KW - Multiple mutations

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=79958056962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958056962&partnerID=8YFLogxK

U2 - 10.3324/haematol.2010.039321

DO - 10.3324/haematol.2010.039321

M3 - Article

C2 - 21357704

AN - SCOPUS:79958056962

VL - 96

SP - 918

EP - 921

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -